GT Biopharma, Inc.
GTBP
$1.14
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.25% | -21.13% | -73.25% | -20.84% | 22.68% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12,955.56% | 86.03% | 81.49% | 96.57% | -100.50% |
| Change in Net Operating Assets | 142.94% | 66.28% | -54.63% | -98.85% | -142.27% |
| Cash from Operations | 11.01% | -8.25% | -45.77% | -12.43% | 2.88% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -21.52% | 741.76% | 166.39% | 375.65% |
| Cash from Investing | -100.00% | -21.52% | 741.76% | 166.39% | 375.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -64.65% | -- | -52.52% | -52.52% | -52.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 118.18% | -- | -52.52% | -52.51% | -52.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.60% | 634.74% | 164.55% | 2,010.93% | 350.17% |